Ovarian Cancer

David M. O'Malley, MD, discusses future research directions with balstilimab and zalifrelimab in patients with cervical cancer.

Ritu Salani, MD, MBA, discussed the clinical rationale to evaluate combination strategies with immunotherapy in ovarian cancer, as well as novel agents in clinical development that could further influence the treatment paradigm.

Ritu Salani, MD, MBA, discusses the scope of ongoing research in advanced ovarian cancer.

Rechallenge with maintenance olaparib following response to platinum-based chemotherapy significantly improved progression-free survival in heavily pretreated patients with relapsed ovarian cancer, irrespective of BRCA status, according to results of the phase 3 OReO/ENGOT Ov-38 study.

Franco Muggia, MD, a fixture at NYU Langone’s Perlmutter Cancer Center and a leader in the study and treatment of patients with gynecologic cancers, died on September 8, 2021. He was 85 years old.

The neo–epitope-based vaccine Tedopi is under investigation either alone or in combination with pembrolizumab as maintenance treatment vs best supportive care in patients with recurrent ovarian cancer following platinum-based chemotherapy as part of the phase 2 TEDOVA trial.

Robert Wenham, MD, MS, FACOG, FACS, discusses the potential for immunotherapy in ovarian cancer.

Sanaz Memarzadeh, MD, PhD, focuses on these ongoing multidisciplinary research directions aimed at improving outcomes for patients with ovarian cancer.

Rachel N. Grisham, MD, discusses the rationale to explore the combination of VS-6766 and defactinib in patients with low-grade serous ovarian cancer.

Lyndsay Willmott, MD, discusses the expanding role for genomic testing in ovarian cancer.

Bradley J. Monk, MD, FACS, FACOG, discusses the utility of PARP inhibitors as frontline maintenance therapy in ovarian cancer.

Rachel N. Grisham, MD, discusses rationale for evaluating binimetinib as a treatment option for patients with low-grade serous ovarian cancer.

David M. O'Malley, MD discusses the utility of chemoimmunotherapy in ovarian cancer.

Dana Chase, MD, FACOG, gynecologic oncologist, discusses the importance of utilizing genetic testing for BRCA mutations in ovarian cancer.

Maintenance niraparib has been shown to result in a significant progression-free survival benefit in patients with BRCA-mutated ovarian cancer following response to platinum-based chemotherapy.

The subcutaneously administered peptide cancer vaccine maveropepimut-S was found to produce promising activity in heavily pretreated patients with recurrent ovarian cancer.

Lyndsay Willmott, MD, discusses the importance of genetic testing in ovarian cancer.

The addition of GEN-1 to standard-of-care neoadjuvant chemotherapy has shown preliminary safety and clinical activity and appears to have an impact on the tumor microenvironment in patients with advanced epithelial ovarian cancer.

Dr. George and Dr. Hurley discuss the data generated from their study on the correlation between deleterious variants in genes and the development of hereditary breast and ovarian cancers in populations throughout the Caribbean.

Bradley J. Monk, MD, FACS, FACOG, discusses the utility of PARP inhibitors as maintenance therapy in ovarian cancer.

Shannon Westin, MD, MPH, discusses the key takeaways from the EFFORT trial, future research directions with adavosertib, and the characteristics of PARP inhibitor resistance in patients with ovarian cancer.

The novel gene-mediated immunotherapy GEN-1 showcased satisfactory safety with an acceptable risk/benefit profile when given over a 6-month period with up to 17 doses in newly diagnosed patients with stage III/IV ovarian cancer.

The lead novel candidate, the WEE1 inhibitor adavosertib, has been tested in more than 50 completed or ongoing clinical studies but has yet to proceed to a phase 3 trial despite showing promising safety and efficacy as monotherapy and in combination with a range of other cancer therapies.

The combination of ceralasertib and olaparib induced clinical activity and was well tolerated in patients with homologous recombination deficient, recurrent platinum-sensitive, PARP inhibitor–resistant ovarian cancer.

David M. O'Malley, MD, discusses the promise of antibody-drug conjugates in ovarian cancer.